BIRC5 and pancreatic adenocarcinoma: When donor cells harbor a dominant‐negative mutant of Survivin (Survivin‐T34A) that blocks the inhibition of apoptosis, the sEVs increased the apoptotic cell death and enhanced the Gemcitabine sensitivity in pancreatic adenocarcinoma.66